Zappasodi, Roberta http://orcid.org/0000-0002-7031-6671
Serganova, Inna
Cohen, Ivan J.
Maeda, Masatomo
Shindo, Masahiro
Senbabaoglu, Yasin
Watson, McLane J.
Leftin, Avigdor
Maniyar, Rachana
Verma, Svena
Lubin, Matthew
Ko, Myat
Mane, Mayuresh M.
Zhong, Hong
Liu, Cailian
Ghosh, Arnab
Abu-Akeel, Mohsen
Ackerstaff, Ellen
Koutcher, Jason A.
Ho, Ping-Chih http://orcid.org/0000-0003-3078-3774
Delgoffe, Greg M. http://orcid.org/0000-0002-2957-8135
Blasberg, Ronald
Wolchok, Jedd D. http://orcid.org/0000-0001-6718-2222
Merghoub, Taha http://orcid.org/0000-0002-1518-5111
Article History
Received: 1 November 2019
Accepted: 3 February 2021
First Online: 15 February 2021
Competing interests
: R.Z. is inventor on patent applications related to work on GITR, PD-1 and CTLA-4. R.Z. is consultant for Leap Therapeutics and iTEOS Belgium SA. Y.S. is currently employed by Genentech and holds equity in Roche. P.-C.H. received research support from Roche-pRED and honorarium from Chungai and Pfizer. P.-C.H. is also a scientific advisory board member of Elixiron Immunotherapeutics and Acepodia. G.M.D. consults for and/or is on the scientific advisory board of BlueSphere Bio, Century Therapeutics, Novasenta, Pieris Pharmaceuticals, and Western Oncolytics/Kalivir; has grants from bluebird bio, Novasenta, Pfizer, Pieris Pharmaceuticals, TCR2, and Kalivir; G.M.D. owns equity in BlueSphere Bio and Novasenta. T.M. is a cofounder and holds an equity in IMVAQ Therapeutics. T.M. is a consultant of Immunos Therapeutics, Pfizer and Immunogenesis. T.M. has research support from Bristol-Myers Squibb; Surface Oncology; Kyn Therapeutics; Infinity Pharmaceuticals, Inc.; Peregrine Pharmaceuticals, Inc.; Adaptive Biotechnologies; Leap Therapeutics, Inc.; and Aprea. T.M. has patents on applications related to work on oncolytic viral therapy, alpha virus-based vaccines, neo-antigen modelling, CD40, GITR, OX40, PD-1 and CTLA-4. J.D.W. is consultant for Adaptive Biotech; Amgen; Apricity; Ascentage Pharma; Astellas; AstraZeneca; Bayer; Beigene; Boehringer Ingelheim; Bristol Myers Squibb; Celgene; Chugai; Eli Lilly; Elucida; F Star; Georgiamune; Imvaq; Kyowa Hakko Kirin; Linneaus; Merck; Neon Therapeutics; Polynoma; Psioxus; Recepta; Takara Bio; Trieza; Truvax; Sellas; Serametrix; Surface Oncology; Syndax; Syntalogic, Werewolf Therapeutics. J.D.W. reports grants from Bristol Myers Squibb and Sephora. J.D.W. has equity in Tizona Pharmaceuticals; Adaptive Biotechnologies; Imvaq; Beigene; Linneaus; Apricity; Arsenal IO; Georgiamune. J.D.W. is inventor on patent applications related to work on DNA vaccines in companion animals with cancer, assays for suppressive myeloid cells in blood, oncolytic viral therapy, alphavirus-based vaccines, neo-antigen modelling, CD40, GITR, OX40, PD-1 and CTLA-4. The other authors declare no competing interests.